Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space ...

Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

PKM2 acts like a switch for cellular energy, directly determining whether cancer cells can rapidly generate energy and biosynthetic precursors to support their continued growth. Using a driving ...

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced today that ...

Rhabdomyolysis is a condition in which muscle damage—often caused by drug intake—can lead to impaired kidney function and ...

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it ...

The 8-Bromo-cAMP sodium salt PKA activator, a synthetic analog of cAMP, is one of the most potent tools of investigating and playing with this pathway, which has become an essential part of ...

BioAtla and GATC Health announce $40 million SPV transaction to advance ozuriftamab vedotin into a registrational trial for 2L+ OPSCC: San Diego Saturday, January 3, 2026, 18:00 H ...

The nonapeptide Oxytocin is a cyclic nine-amino‐acid peptide that has long been studied for its possible roles in ...

Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...